Hope S. Rugo, MD, is the Director of the Women's Cancers Program, the Division Chief of Breast Medical Oncology, and a Professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center. She is also a Professor Emeritus at UCSF

Elacestrant Combinations in ER+/HER2- Locally Advanced or Metastatic Breast Cancer: Efficacy and Safety Updates from the Phase 1b/2 ELEVATE Study

Funding supported by Stemline Therapeutics. Content independently developed by OncLive

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Presented by Dr. Hope S. Rugo, this slide deck presents updated phase 1b/2 safety and efficacy results from the ELEVATE trial of elacestrant combinations with ribociclib and everolimus in ER+/HER2- metastatic breast cancer, highlighting their clinical activity and potential as an endocrine therapy backbone.